HDAC4 Inhibitors as Antivascular Senescence Therapeutics

Huang, Chuoji; Lin, Zhongxiao; Liu, Xiaoyan; Ding, Qian; Cai, Jianghong; Zhang, Zhongyi; Rose, Peter; Zhu, Yi Zhun

Abstract

Aging is an inevitable consequence of life, and during this process, the epigenetic landscape changes and reactive oxygen species (ROS) accumulation increases. Inevitably, these changes are common in many age-related diseases, including neurodegeneration, hypertension, and cardiovascular diseases. In the current research, histone deacetylation 4 (HDAC4) was studied as a potential therapeutic target in vascular senescence. HDAC4 is a specific class II histone deacetylation protein that participates in epigenetic modifications and deacetylation of heat shock proteins and various transcription factors. There is increasing evidence to support that HDAC4 is a potential therapeutic target, and developments in the synthesis and testing of HDAC4 inhibitors are now gaining interest from academia and the pharmaceutical industry.

Citation

Huang, C., Lin, Z., Liu, X., Ding, Q., Cai, J., Zhang, Z., Rose, P., & Zhu, Y. Z. (2022). HDAC4 Inhibitors as Antivascular Senescence Therapeutics. Oxidative Medicine and Cellular Longevity, 2022, 1-12. https://doi.org/10.1155/2022/3087916

• Journal Article Type: Review
• Acceptance Date: Jun 8, 2022
• Online Publication Date: Jun 29, 2022
• Publication Date: Jun 29, 2022
• Deposit Date: Nov 8, 2023
• Publicly Available Date: Nov 10, 2023
• Journal: Oxidative Medicine and Cellular Longevity
• Print ISSN: 1942-0900
• Electronic ISSN: 1942-0994
• Publisher: Hindawi
• Peer Reviewed: Peer Reviewed
• Volume: 2022
• Article Number: 087916
• Pages: 1-12
• DOI: https://doi.org/10.1155/2022/3087916
• Keywords: Cell Biology; Aging; General Medicine; Biochemistry
• Public URL: https://nottingham-repository.worktribe.com/output/9410836
• Publisher URL: https://www.hindawi.com/journals/omcl/2022/3087916/